1
|
Hua H, Wang J, Zhong P, Mou T, Liu P, Xie F. The clinical prognostic value of lncRNA LINC00675 in cancer patients: A meta-analysis. Medicine (Baltimore) 2021; 100:e25244. [PMID: 33879657 PMCID: PMC8078383 DOI: 10.1097/md.0000000000025244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 03/02/2021] [Indexed: 01/04/2023] Open
Abstract
A newly discovered long non-coding RNA (lncRNA) is associated with the progression of a variety of tumors. The purpose of this meta-analysis is to explore further the relationship between clinicopathological features and the prognostic value of LINC00675 in caners.We searched the various database, including PubMed, Web of Science, Cochrane Library, Embase together with Wanfang, and China National Knowledge Infrastructure for articles on LINC00675 and clinicopathological characteristics and prognosis of patients with cancers before February 20, 2020. According to the inclusion and exclusion criteria, the studies that meet the criteria were systematically collected through search keywords. The Newcastle Ottawa document quality assessment system was used to evaluate the quality of documents. The required data from literature were extracted, and the hazard ratio (HR), odds ratio (OR), and 95confidence interval (CI) were calculated using stata12.0 software and RevMan5.3 software.A total of 5 studies covering 462 patients were included in this meta-analysis to evaluate the prognostic value of LINC00675 in cancers. Our results showed that high LINC00675 expression was significantly correlated with poor overall survival (OS) (HR = 1.60, 95% CI: 1.23-2.08, P = .0005). Additionally, upregulated expression of LINC00675 was significantly associated with tumor node metastasis stage (OR = 1.74, 95% CI: 1.18-2.58, P = .006) and distant metastasis (OR = 2.22, 95% CI: 1.21-4.08, P = .01).Our study suggests that LINC00675 could be used as a biomarker to evaluate the prognosis of cancer patients. More studies to further confirm that the clinical value of LINC00675 in cancers will be required.
Collapse
|
2
|
The role of FOXD2-AS1 in cancer: a comprehensive study based on data mining and published articles. Biosci Rep 2021; 40:226886. [PMID: 33140822 PMCID: PMC7670568 DOI: 10.1042/bsr20190372] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 10/29/2020] [Accepted: 10/30/2020] [Indexed: 01/04/2023] Open
Abstract
Background and aims: Long non-coding RNA (lncRNA) FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) is aberrantly expressed in various cancers and associated with cancer progression. A comprehensive meta-analysis was performed based on published literature and data in the Gene Expression Omnibus database, and then the Cancer Genome Atlas (TCGA) dataset was used to assess the clinicopathological and prognostic value of FOXD2-AS1 in cancer patients. Methods: Gene Expression Omnibus databases of microarray data and published articles were used for meta-analysis, and TCGA dataset was also explored using the GEPIA analysis program. Hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the role of FOXD2-AS1 in cancers. Results: This meta-analysis included 21 studies with 2391 patients and 25 GEO datasets with 3311 patients. The pooled HRs suggested that highly expressed FOXD2-AS1 expression was correlated with poor overall survival (OS) and disease-free survival (DFS). Similar results were obtained by analysis of TCGA data for 9502 patients. The pooled results also indicated that FOXD2-AS1 expression was associated with bigger tumor size and advanced TNM stage, but was not related to age, gender, differentiation and lymph node metastasis. Conclusion: The present study demonstrated that FOXD2-AS1 is closely related to tumor size and TNM stage. Additionally, increased FOXD2-AS1 was a risk factor of OS and DFS in cancer patients, suggesting FOXD2-AS1 may be a potential biomarker in human cancers.
Collapse
|
3
|
Liang C, Zhang Y, Zhang Y, Li R, Wang Z, Wei Z, Guo J. The prognostic value of LINC01296 in pan-cancers and the molecular regulatory mechanism in hepatocellular carcinoma: a comprehensive study based on data mining, bioinformatics, and in vitro validation. Onco Targets Ther 2019; 12:5861-5885. [PMID: 31410029 PMCID: PMC6650622 DOI: 10.2147/ott.s205853] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Accepted: 06/21/2019] [Indexed: 12/12/2022] Open
Abstract
Background and aims This study aimed to clarify the prognostic role of LINC01296 in various cancers, and to evaluate its effect on proliferation, metastasis, and the cell cycle in hepatocellular carcinoma (HCC) by data mining, bioinformatics, and in vitro validation. Methods The prognostic role of LINC01296 in cancer patients was assessed by searching the PubMed, Embase, Web of Science, and Gene Expression Omnibus databases and calculating pooled hazard ratios (HRs) with 95% confidence intervals (CIs); this prognostic role was also evaluated using The Cancer Genome Atlas (TCGA). We detected LINC01296 expression in HCC cell lines, and lentivirus-mediated small interfering RNAs were used to silence LINC01296 in MHCC97H and Hep3B cells to explore the role of LINC01296 in cell proliferation, metastasis, and cell cycle progression with in vitro validation and bioinformatics. Results The results indicated that LINC01296 overexpression was associated with poor overall survival (OS) and disease-free survival (DFS) in various cancers; however, LINC01296 expression was not associated with recurrence-free survival (RFS). Similar results were found with TCGA, which showed that LINC01296 expression was associated with the pathologic stage, tumor size, and differentiation in Asian cancer patients. Additionally, bioinformatics analysis revealed expression of 394 related genes, which indicated that LINC01296 could be involved in the tumorigenesis and progression of HCC. In vitro gene silencing experiments indicated that LINC01296 downregulation repressed cell proliferation, cell cycle progression, and the metastatic potential of HCC through the regulation of BUB1, CCNA2, and CDK1 expression. Conclusion This study demonstrated that LINC01296 expression is related to poor OS and DFS in a variety of cancer types and that LINC01296 has an oncogenic role in HCC.
Collapse
Affiliation(s)
- Chaojie Liang
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| | - Yongping Zhang
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| | - Yu Zhang
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| | - Ruihuan Li
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| | - Zhimin Wang
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| | - Zhigang Wei
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| | - Jiansheng Guo
- Department of General Surgery, First Hospital/First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China
| |
Collapse
|
4
|
Wang L, Xie Y, Fang H, Zhang X, Pan H, Yan S. Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics. Cancer Manag Res 2019; 11:6581-6592. [PMID: 31410056 PMCID: PMC6643155 DOI: 10.2147/cmar.s200922] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 06/10/2019] [Indexed: 02/06/2023] Open
Abstract
Background Differentiation antagonizing non-protein-coding RNA (DANCR) is a novel long noncoding RNA. Recent studies have shown that DANCR is aberrantly expressed in several types of cancer and is associated with poor outcomes. However, the clinical diagnostic significance of DANCR in tumors is not completely understood. Methods We searched the PubMed, Medline, Web of Science, EMBASE, Cochrane Library, and Ovid databases (up to December 30, 2018) for relevant literature. A total of 11 studies with 945 cancer patients were included in the present meta-analysis. We further validated the results using The Cancer Genome Atlas (TCGA) dataset. Results High expression of DANCR significantly predicted poor overall survival (low expression group vs high expression group; HR =0.56, 95% CI=[0.43, 0.72], =0.000); this was validated using TCGA. Moreover, DANCR expression was associated with advanced tumor node metastasis stage (I+II:III+IV; OR=0.22, 95% CI=[0.14, 0.35], P=0.001) and lymph node metastasis (no:yes; OR=0.21, 95% CI=[0.13, 0.35], P=0.001). Conclusion Our results suggest that elevated DANCR is related to poor clinical outcomes and could serve as a potential prognostic biomarker of cancer.
Collapse
Affiliation(s)
- Lihong Wang
- Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| | - Yalin Xie
- Department of Radiotherapy, Hangzhou Tumor Hospital, Hangzhou 310000, Zhejiang, People's Republic of China
| | - Hui Fang
- Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| | - Xia Zhang
- Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| | - Huiyun Pan
- Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| | - Senxiang Yan
- Department of Radiotherapy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| |
Collapse
|
5
|
Qu R, Chen X, Zhang C. LncRNA ZEB1-AS1/miR-409-3p/ZEB1 feedback loop is involved in the progression of non-small cell lung cancer. Biochem Biophys Res Commun 2018; 507:450-456. [PMID: 30448056 DOI: 10.1016/j.bbrc.2018.11.059] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Accepted: 11/11/2018] [Indexed: 02/06/2023]
Abstract
Emerging evidence has illustrated that long noncoding RNA (LncRNA) ZEB1 antisense RNA 1 (ZEB1-AS1) involved in the development of various type of human cancers. However, the role of ZEB1-AS1 in non-small cell lung cancer (NSCLC) is still elusive and poorly understood. The present study aimed to provide functional evidence and elucidate the molecular mechanisms by which the ZEB1-AS1 promotes oncogenesis of NSCLC. Our study found that ZEB1-AS1 was upregulated in NSCLC cells and knockdown of ZEB1-AS1 significantly inhibited cell growth and induced cell apoptosis. Mechanically, miR-409-3p was confirmed as a direct target of ZEB1-AS1 and negatively regulated by ZEB1-AS1 via competing endogenous RNA (ceRNA) mechanism; miR-409-3p inhibited ZEB1 expression by directly binding to the 3'UTR. Importantly, as predicted by JASPAR and further confirmed by luciferase reporter gene and ChIP assays, we found ZEB1 could bind to the promoter region of ZEB1-AS1 to activate its expression. Restoration of ZEB1 could partially abolished the action of ZEB1-AS1 silencing on cell proliferation and apoptosis. Collectively, the results suggested that ZEB1-AS1/miR-409-3p/ZEB1 constitutes a positive feedback loop to promote the tumorigenesis of NSCLC, highlighting the possibility of improving NSCLC treatment by targeting the ZEB1-AS1 signaling pathway.
Collapse
Affiliation(s)
- Ruize Qu
- Cheeloo College of Medicine, Shandong University, Jinan, 250100, PR China
| | - Xiaomin Chen
- Cheeloo College of Medicine, Shandong University, Jinan, 250100, PR China
| | - Chao Zhang
- School of Basic Medical Sciences, Shandong University, Jinan, 250100, PR China.
| |
Collapse
|
6
|
Zhang F, Chen X, Xi K, Qiu Z, Wang Y, Gui Y, Hou Y, Chen K, Zhang X. Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review. Onco Targets Ther 2018; 11:7827-7840. [PMID: 30464530 PMCID: PMC6225848 DOI: 10.2147/ott.s184303] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background and aims: HOXD antisense growth-associated long noncoding RNA (HOXD-AS1) was reported to be upregulated in various cancers, such as gastric cancer, hepatocellular carcinoma, colorectal cancer, and glioma. Here, we conducted a meta-analysis and The Cancer Genome Atlas data review to investigate the clinicopathologic and prognostic value of HOXD-AS1 in patients with malignant tumors. Materials and methods: Systematic literatures were searched from PubMed, Medline, Cochrane Library, Web of Science, EMBASE database, Ovid, Chinese CNKI, and the Chinese WanFang database. The role of HOXD-AS1 in cancers was evaluated by pooled ORs and HRs with 95% CIs. The Cancer Genome Atlas dataset was used to explore the prognostic value of HOXD-AS1 in various cancers.
Collapse
Affiliation(s)
- Fuhong Zhang
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Xiaowan Chen
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Kehu Xi
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Zhiqiang Qiu
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Youhu Wang
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Yan Gui
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Yun Hou
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Kangbing Chen
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| | - Xiaobing Zhang
- Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
| |
Collapse
|
7
|
Shen X, Piao L, Zhang S, Cui Y, Cui Y, Quan X, Sun H. Long non-coding RNA activated by TGF-β expression in cancer prognosis: A meta-analysis. Int J Surg 2018; 58:37-45. [PMID: 30121307 DOI: 10.1016/j.ijsu.2018.08.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 07/22/2018] [Accepted: 08/06/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND Recently, long non-coding RNA activated by transforming growth factor beta (TGF-β) (lncRNA ATB) was shown to be useful in cancer prognosis, however, its prognostic value in human cancer has been inconsistent. Our study aimed to explore the prognostic role of lncRNA ATB expression in cancer prognosis. METHODS PubMed, Embase, and Cochrane Library databases were thoroughly searched to retrieve studies focusing on the prognostic role of lncRNA ATB expression in cancer, and meta-analysis was performed. RESULTS A total of 15 studies were included into this meta-analysis. High lncRNA ATB expression was significantly related to shorter overall survival (OS) (HR = 2.44, 95%CI = 1.98-3.01, P < 0.01), recurrence-free survival (RFS) (HR = 1.85, 95%CI = 1.42-2.40, P < 0.01), disease-free survival (DFS) (HR = 3.61, 95%CI = 2.45-5.33, P < 0.01), and progression-free survival (PFS) (HR = 2.97, 95%CI = 2.12-4.16, P < 0.01) when compared with low lncRNA ATB expression in cancer. Moreover, Patients with high lncRNA ATB expression tended to have worse tumor differentiation (P < 0.01), more advanced clinical stage (P < 0.01), deeper tumor invasion (P < 0.01), earlier distant metastases (P = 0.02), lymph node metastases (P = 0.04), and vascular invasion (P < 0.01) when compared with those with low lncRNA ATB expression. CONCLUSIONS High lncRNA ATB expression was significantly associated with worse prognosis in cancer. LncRNA ATB expression could be used as a prognostic biomarker for human cancer.
Collapse
Affiliation(s)
- Xionghu Shen
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China
| | - Longzhen Piao
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China
| | - Songnan Zhang
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China
| | - Yan Cui
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China
| | - Yuzhen Cui
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China
| | - Xianglan Quan
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China
| | - Honghua Sun
- Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, 133000, Jilin Province, China.
| |
Collapse
|